Gene Therapy in Ophthalmology Market Driven by Growing Prevalence of Eye Diseases

The gene therapy in ophthalmology market is evolving rapidly to address the growing prevalence of eye diseases and disorders. Gene therapy offers advantages over conventional drug therapies by delivering corrective genetic material directly into retinal cells, resulting in long-lasting treatment effects. It holds promise for treating various inherited retinal diseases that currently have no cure.

The gene therapy in ophthalmology market is estimated to be valued at USD 1.2 Bn in 2024 and is expected to reach USD 5.8 Bn by 2031, growing at a compound annual growth rate (CAGR) of 25.2% from 2024 to 2031.

The growing prevalence of eye diseases like age-related macular degeneration, diabetic retinopathy and retinal vein occlusion is driving the demand for effective treatment options. Gene Therapy in Ophthalmology Market offers long-lasting effects and could emerge as an important treatment modality for various blinding retinal diseases.


Get More Insights - https://herentmi.livepositivel........y.com/gene-thera

Explore More Related Articles - https://www.coherentmi.com/blo........g/sacroiliac-joi